Abiprubart is under clinical development by Kiniksa Pharmaceuticals and currently in Phase II for Sicca Syndrome (Sjogren). According to GlobalData, Phase II drugs for Sicca Syndrome (Sjogren) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Abiprubart LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Abiprubart overview
Abiprubart is under development for the treatment of rheumatoid arthritis and Sjogren’s disease. It is administered through intravenous or subcutaneous route. The drug candidate is a monoclonal antibody. It acts by targeting CD40 ligand.
It was also under development for the treatment of focal segmental glomerulosclerosis (FSGS), autoimmune diseases including T-cell-dependent, B-cell-mediated diseases, such as pemphigus/pemphigoid, myasthenia gravis, or graft versus host disease, sicca syndrome, systemic lupus erythematosus, type 1 diabetes, ulcerative colitis, lupus nephritis, hidradenitis suppurativa, transplant rejection of heart, pancreatic islet and kidney, idiopathic thrombocytopenic purpura.
Kiniksa Pharmaceuticals overview
Kiniksa Pharmaceuticals (Kiniksa) is a biopharmaceutical company that discovers, acquires, develops and commercializes medicines to treat autoinflammatory and autoimmune diseases. The company’s pipeline products include rilonacept drug for the treatment of recurrent pericarditis; mavrilimumab, against giant cell arteritis, COVID-19 and hyper inflammation; vixarelimab, targeting prurigo nodularis and diseases characterized by chronic pruritus; KPL-404, a monoclonal antibody to treat T-cell dependent, B-Cell–mediated indications. It develops medicines in the therapeutic areas of cardiovascular, dermatology and autoimmune diseases. The company operates in Bermuda, the US and the UK. Kiniksa is headquartered in Hamilton, Bermuda.
For a complete picture of Abiprubart’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.